Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duobrii in Acne Keloidalis Nuchae
NCT05608499Phase 3Terminated
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Oct 2022
- Primary completion
- Apr 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of halobetasol propionate + tazarotene in acne keloidalis nuchae (AKN), sponsored by Icahn School of Medicine at Mount Sinai. Started Oct 2022; status: terminated.
02
Drugs
halobetasol propionate + tazarotene
03
Conditions
acne keloidalis nuchae (AKN)
Beyond the preview
Go deeper on NCT05608499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05608499.